Adenovirus vaccine

Adenovirus vaccine

An adenovirus vaccine is a vaccine against Adenovirus.[1]

Bottles of the vaccine.

It was used by the United States military from 1971 to 1999, but was discontinued when the only manufacturer stopped production.[2][3] This vaccine elicited immunity to serotypes 4 and 7.[4] On March 16, 2011, the U.S. Food and Drug Administration approved an adenovirus vaccine manufactured by Teva Pharmaceuticals under contract to the U.S. Army. [5]This vaccine is essentially the same as the one used from 1971 to 1999. On October 24, 2011 the military services began administering the new adenovirus vaccine to recruits during basic training. In its first year of use, adenovirus vaccine prevented 15,000 cases of Febrile Respiratory Illness, as evidenced by a reduction in the rate of Febrile Respiratory Illness that began soon after October 2011.

It should not be confused with the strategy of using adenovirus as a carrier to develop vaccines for other pathogens, or as a general gene carrier.[6][7][8]


  1. ^ Tucker SN, Tingley DW, Scallan CD (February 2008). "Oral adenoviral-based vaccines: historical perspective and future opportunity". Expert Rev Vaccines 7 (1): 25–31.  
  2. ^ Russell KL, Hawksworth AW, Ryan MA, et al. (April 2006). "Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004". Vaccine 24 (15): 2835–42.  
  3. ^ "Vaccine Trials For "Boot Camp Crud" May Help 20 Percent of Recruits". Archived from the original on 12 February 2009. Retrieved 2009-01-15. 
  4. ^ Centers for Disease Control and Prevention (CDC) (July 2001). "Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000". MMWR Morb. Mortal. Wkly. Rep. 50 (26): 553–5.  
  5. ^ Malarkey MA, Baylor NW. FDA approval letter dated March 16, 2011.
  6. ^ Croyle MA, Patel A, Tran KN, et al. (2008). Doolan, Denise L., ed. "Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice". PLoS ONE 3 (10): e3548.  
  7. ^ Hartman ZC, Appledorn DM, Amalfitano A (March 2008). "Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications". Virus Res. 132 (1–2): 1–14.  
  8. ^ Tatsis N, Ertl HC (October 2004). "Adenoviruses as vaccine vectors". Mol. Ther. 10 (4): 616–29.